The outbreak of the SARS-CoV-2 virus caused a sudden shift in focus for the pharmaceutical industry. After the genetic sequence of the virus was released in early 2020, manufacturers across the globe began the race to research and develop vaccines to combat the virus. In order to avoid the development delays that would occur due to a limited number of qualified BSL-3 facilities, Q² Solutions pivoted their approach to solve the problem before it could even start. Learn more about our efforts to combat COVID-19 in our new eBook.

Complete the form to access this vaccine eBook